Medicare Enrolled
Dr. Eknath Deo, M.D., F.A.C.P.
Hematology & Oncology · Long Beach, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Deo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Deo?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Deo
Dr. Eknath Deo is a hematology & oncology specialist in Long Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Deo performed 7,483 Medicare services across 529 unique beneficiaries.
Between the years covered by Open Payments, Dr. Deo received a total of $7,952 from 43 pharmaceutical and/or device companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Deo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 30% volume in CA
$7,952 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,483
Medicare services
Top 30% in CA for hematology & oncology
529
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~394 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 3,661 | $18 | $47 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,355 | $0 | $0 |
| Injection, granisetron hydrochloride, 100 mcg | 640 | $0 | $1 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
359 | $27 | $65 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
290 | $106 | $248 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
163 | $123 | $301 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
162 | $12 | $31 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
108 | $72 | $191 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
105 | $152 | $384 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
99 | $1 | $2 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
94 | $12 | $30 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
78 | $100 | $196 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
74 | $1 | $20 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
69 | $60 | $148 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
64 | $1 | $1 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
53 | $59 | $147 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
43 | $68 | $159 |
| Oxygen chamber therapy management This code covers the professional management and oversight of a patient undergoing oxygen chamber therapy. It involves monitoring the patient's response and adjusting the treatment plan as needed. |
37 | $88 | $200 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
16 | $71 | $214 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
13 | $46 | $123 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.5% high complexity
79.1% medium
11.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,952
Total received (2018-2024)
Avg $1,136/year across 7 years
Top 35% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
330
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,595 (95.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$357 (4.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$69
2023
$1,033
2022
$2,107
2021
$2,053
2020
$764
2019
$994
2018
$932
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$69
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,295
Amgen Inc.
$1,228
E.R. Squibb & Sons, L.L.C.
$778
Janssen Biotech, Inc.
$707
Coherus Biosciences Inc.
$507
Incyte Corporation
$358
Celgene Corporation
$307
Merck Sharp & Dohme Corporation
$299
Novartis Pharmaceuticals Corporation
$272
Merck Sharp & Dohme LLC
$181
Genentech USA, Inc.
$177
Pharmacyclics LLC, An AbbVie Company
$177
PFIZER INC.
$161
Clovis Oncology, Inc.
$143
Astellas Pharma US Inc
$124
Kite Pharma, Inc.
$118
Ipsen Biopharmaceuticals, Inc
$117
Regeneron Healthcare Solutions, Inc.
$93
Exelixis Inc.
$79
AVEO Pharmaceuticals, Inc.
$73
AMAG Pharmaceuticals, Inc.
$71
EISAI INC.
$69
Gilead Sciences, Inc.
$56
GENZYME CORPORATION
$54
BeiGene USA, Inc.
$47
Lilly USA, LLC
$47
Daiichi Sankyo Inc.
$36
Teva Pharmaceuticals USA, Inc.
$34
Karyopharm Therapeutics Inc.
$33
Bayer HealthCare Pharmaceuticals Inc.
$29
CTI BioPharma Corp.
$27
Bayer Healthcare Pharmaceuticals Inc.
$27
Myovant Sciences Inc.
$25
Spectrum Pharmaceuticals Inc.
$25
EMD Serono, Inc.
$24
Eisai Inc.
$22
Puma Biotechnology, Inc.
$22
MorphoSys, US Inc.
$21
Sobi, Inc
$20
Sun Pharmaceutical Industries Inc.
$19
Takeda Pharmaceuticals U.S.A., Inc.
$18
Octapharma USA, Inc.
$17
INSYS Therapeutics Inc
$13
Top 3 companies account for 41.5% of all-time payments
Associated products mentioned in payments ›
ABECMA · Alecensa · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CALQUENCE · Cabometyx · DARZALEX · DOPTELET · EPKINLY · ERBITUX · ERLEADA · Enhertu · Erleada · FERAHEME · FOTIVDA · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MONJUVI · MVASI · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · PIQRAY · Padcev · Perjeta · Pomalyst · Prolia · REBLOZYL · Revlimid · Rubraca · SANDOSTATIN LAR · SOMATULINE DEPOT · SYNDROS · Somatuline Depot · TASIGNA · TECENTRIQ · Trodelvy · Udenyca · VERZENIO · Vectibix · Vonjo · XGEVA · XPOVIO · XTANDI · YONSA · Yescarta · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
413
Per 100K population
4.2
County median income
$87,760
Nearest hospital
MEMORIALCARE LONG BEACH MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Deo is a mixed practice specialist, with above-average Medicare volume (top 30% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Deo experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Deo performed 3,661 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Deo receive payments from pharmaceutical companies?
Yes. Dr. Deo received a total of $7,952 from 43 companies across 330 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Deo's costs compare to other hematology & oncology specialists in Long Beach?
Dr. Deo's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Deo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Long Beach
Browse hematology & oncology specialists in Long Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology